Cargando…
Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases
OBJECTIVE: To evaluate the trends in disease burden and the epidemiological features of liver cancer in China while identifying potential strategies to lower the disease burden. DESIGN: Observational study based on the Global Burden of Diseases. PARTICIPANTS: Data were publicly available and de-iden...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500226/ https://www.ncbi.nlm.nih.gov/pubmed/31015269 http://dx.doi.org/10.1136/bmjopen-2018-025613 |
_version_ | 1783415907034333184 |
---|---|
author | Ding, Cheng Fu, Xiaofang Zhou, Yuqing Liu, Xiaoxiao Wu, Jie Huang, Chenyang Deng, Min Li, Yiping Li, Lanjuan Yang, Shigui |
author_facet | Ding, Cheng Fu, Xiaofang Zhou, Yuqing Liu, Xiaoxiao Wu, Jie Huang, Chenyang Deng, Min Li, Yiping Li, Lanjuan Yang, Shigui |
author_sort | Ding, Cheng |
collection | PubMed |
description | OBJECTIVE: To evaluate the trends in disease burden and the epidemiological features of liver cancer in China while identifying potential strategies to lower the disease burden. DESIGN: Observational study based on the Global Burden of Diseases. PARTICIPANTS: Data were publicly available and de-identified and individuals were not involved. MEASUREMENT AND METHODS: To measure the liver cancer burden, we extracted data from the Global Health Data Exchange using the metrics of prevalence, incidence, mortality and disability-adjusted life years (DALYs). Joinpoint and negative binomial regressions were applied to identify trends and risk factors. RESULTS: From 1997 to 2016, the prevalence, incidence, mortality and DALYs of liver cancer in China were from 28.22/100 000 to 60.04/100 000, from 27.33/100 000 to 41.40/100 000, from 27.40/100 000 to 31.49/100 000 and from 10 311 308 to 11 539 102, respectively. The prevalence, incidence and mortality were increasing, with the average annual percent changes (AAPCs) of 4.0% (95% CI 3.9% to 4.2%), 2.1% (95% CI 2.0% to 2.2%) and 0.5% (95% CI 0.2% to 0.9%), respectively. Meanwhile, the rate of DALYs was stable with the AAPCs of −0.1% (95% CI −0.4% to 0.3%). The mortality-to-incidence ratio of liver cancer decreased from 1.00 in 1997 to 0.76 in 2016 (β=−0.014, p<0.0001). Males (OR: 2.98, 95% CI 2.68 to 3.30 for prevalence, OR: 2.45, 95% CI 2.21 to 2.71 for incidence) and the elderly individuals (OR: 1.57, 95% CI 1.55 to 1.59 for prevalence, OR: 1.58, 95% CI 1.56 to 1.60 for incidence) had a higher risk. Hepatitis B accounted for the highest proportion of liver cancer cases (55.11%) and deaths (54.13%). CONCLUSIONS: The disease burden of liver cancer continued to increase in China with viral factors as one of the leading causes. Strategies such as promoting hepatitis B vaccinations, blocking the transmission of hepatitis C and reducing alcohol consumption should be prioritised. |
format | Online Article Text |
id | pubmed-6500226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-65002262019-05-21 Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases Ding, Cheng Fu, Xiaofang Zhou, Yuqing Liu, Xiaoxiao Wu, Jie Huang, Chenyang Deng, Min Li, Yiping Li, Lanjuan Yang, Shigui BMJ Open Epidemiology OBJECTIVE: To evaluate the trends in disease burden and the epidemiological features of liver cancer in China while identifying potential strategies to lower the disease burden. DESIGN: Observational study based on the Global Burden of Diseases. PARTICIPANTS: Data were publicly available and de-identified and individuals were not involved. MEASUREMENT AND METHODS: To measure the liver cancer burden, we extracted data from the Global Health Data Exchange using the metrics of prevalence, incidence, mortality and disability-adjusted life years (DALYs). Joinpoint and negative binomial regressions were applied to identify trends and risk factors. RESULTS: From 1997 to 2016, the prevalence, incidence, mortality and DALYs of liver cancer in China were from 28.22/100 000 to 60.04/100 000, from 27.33/100 000 to 41.40/100 000, from 27.40/100 000 to 31.49/100 000 and from 10 311 308 to 11 539 102, respectively. The prevalence, incidence and mortality were increasing, with the average annual percent changes (AAPCs) of 4.0% (95% CI 3.9% to 4.2%), 2.1% (95% CI 2.0% to 2.2%) and 0.5% (95% CI 0.2% to 0.9%), respectively. Meanwhile, the rate of DALYs was stable with the AAPCs of −0.1% (95% CI −0.4% to 0.3%). The mortality-to-incidence ratio of liver cancer decreased from 1.00 in 1997 to 0.76 in 2016 (β=−0.014, p<0.0001). Males (OR: 2.98, 95% CI 2.68 to 3.30 for prevalence, OR: 2.45, 95% CI 2.21 to 2.71 for incidence) and the elderly individuals (OR: 1.57, 95% CI 1.55 to 1.59 for prevalence, OR: 1.58, 95% CI 1.56 to 1.60 for incidence) had a higher risk. Hepatitis B accounted for the highest proportion of liver cancer cases (55.11%) and deaths (54.13%). CONCLUSIONS: The disease burden of liver cancer continued to increase in China with viral factors as one of the leading causes. Strategies such as promoting hepatitis B vaccinations, blocking the transmission of hepatitis C and reducing alcohol consumption should be prioritised. BMJ Publishing Group 2019-04-23 /pmc/articles/PMC6500226/ /pubmed/31015269 http://dx.doi.org/10.1136/bmjopen-2018-025613 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Epidemiology Ding, Cheng Fu, Xiaofang Zhou, Yuqing Liu, Xiaoxiao Wu, Jie Huang, Chenyang Deng, Min Li, Yiping Li, Lanjuan Yang, Shigui Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases |
title | Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases |
title_full | Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases |
title_fullStr | Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases |
title_full_unstemmed | Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases |
title_short | Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases |
title_sort | disease burden of liver cancer in china from 1997 to 2016: an observational study based on the global burden of diseases |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500226/ https://www.ncbi.nlm.nih.gov/pubmed/31015269 http://dx.doi.org/10.1136/bmjopen-2018-025613 |
work_keys_str_mv | AT dingcheng diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT fuxiaofang diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT zhouyuqing diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT liuxiaoxiao diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT wujie diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT huangchenyang diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT dengmin diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT liyiping diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT lilanjuan diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases AT yangshigui diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases |